PE20260298A1 - Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham - Google Patents

Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham

Info

Publication number
PE20260298A1
PE20260298A1 PE2025002847A PE2025002847A PE20260298A1 PE 20260298 A1 PE20260298 A1 PE 20260298A1 PE 2025002847 A PE2025002847 A PE 2025002847A PE 2025002847 A PE2025002847 A PE 2025002847A PE 20260298 A1 PE20260298 A1 PE 20260298A1
Authority
PE
Peru
Prior art keywords
ham
htlv
therapeutic
treatment
prophylactic agent
Prior art date
Application number
PE2025002847A
Other languages
English (en)
Spanish (es)
Inventor
Kaoru Uchimaru
Makoto Yamagishi
Izumi Ishizaki
Yoshihisa Yamano
Original Assignee
Univ School St Marianna Medicine
Univ Tokyo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ School St Marianna Medicine, Univ Tokyo filed Critical Univ School St Marianna Medicine
Publication of PE20260298A1 publication Critical patent/PE20260298A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2025002847A 2018-07-19 2019-07-19 Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham PE20260298A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018135925 2018-07-19
PCT/JP2019/028431 WO2020017629A1 (ja) 2018-07-19 2019-07-19 Htlv-1関連脊髄症(ham)治療又は予防剤、及びhamの治療方法

Publications (1)

Publication Number Publication Date
PE20260298A1 true PE20260298A1 (es) 2026-02-10

Family

ID=69163691

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2025002847A PE20260298A1 (es) 2018-07-19 2019-07-19 Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham
PE2021000080A PE20211376A1 (es) 2018-07-19 2019-07-19 Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2021000080A PE20211376A1 (es) 2018-07-19 2019-07-19 Agente terapeutico o profilactico para la mielopatia asociada al htlv-1 (ham), y metodo de tratamiento del ham

Country Status (16)

Country Link
US (1) US20210269535A1 (cg-RX-API-DMAC7.html)
EP (2) EP4656657A3 (cg-RX-API-DMAC7.html)
JP (4) JP7150286B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210034055A (cg-RX-API-DMAC7.html)
CN (4) CN116850291A (cg-RX-API-DMAC7.html)
AU (1) AU2019306721B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021000949A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112511A1 (cg-RX-API-DMAC7.html)
IL (1) IL280257A (cg-RX-API-DMAC7.html)
MX (1) MX2021000732A (cg-RX-API-DMAC7.html)
PE (2) PE20260298A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550134A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100561QA (cg-RX-API-DMAC7.html)
TW (2) TWI825131B (cg-RX-API-DMAC7.html)
WO (1) WO2020017629A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202101113B (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2025070749A1 (cg-RX-API-DMAC7.html) * 2023-09-29 2025-04-03

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1442749A1 (en) * 2003-01-31 2004-08-04 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of anti-CD100 antibodies for the treatment and the diagnosis of inflammatory disorder affecting the central nervous system
WO2005087268A1 (ja) * 2004-03-11 2005-09-22 Bioclues, Inc 軸索再生促進剤
US8962803B2 (en) 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
CN102131571B (zh) 2008-09-02 2014-03-05 东丽电池隔膜株式会社 微孔性高分子膜、该膜的制备方法及该膜作为电池隔膜的应用
JP5552630B2 (ja) 2008-10-24 2014-07-16 学校法人 聖マリアンナ医科大学 Htlv−i関連脊髄症を治療または予防するための医薬、およびhtlv−i関連脊髄症の患者に対する抗体療法の効果を試験する方法
KR102284780B1 (ko) 2009-12-09 2021-08-02 미쓰비시 타나베 파마 코퍼레이션 T 세포 활성화 저해제, 이것을 함유하는 의약 조성물 및 t 세포 활성화 저해 물질의 스크리닝 방법
CA2824515C (en) * 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
JP5963233B2 (ja) * 2011-12-07 2016-08-03 学校法人 聖マリアンナ医科大学 Htlv−1関連脊髄症を治療または予防するための医薬および前記医薬を用いた抗体療法の治療効果の確認方法
JP6310845B2 (ja) * 2012-07-06 2018-04-11 学校法人 聖マリアンナ医科大学 Htlv−1関連脊髄症患者の治療方法および治療剤
WO2016038084A1 (en) 2014-09-10 2016-03-17 AbbVie Deutschland GmbH & Co. KG Rgma fragment based diagnostic assay
CA2983898A1 (en) * 2015-04-28 2016-11-03 Mitsubishi Tanabe Pharma Corporation Rgma binding protein and use thereof
WO2017189963A1 (en) * 2016-04-29 2017-11-02 Voyager Therapeutics, Inc. Compositions for the treatment of disease
TW202523689A (zh) * 2016-06-01 2025-06-16 美商艾伯維有限公司 治療脊髓損傷及疼痛之方法
US10772887B2 (en) * 2016-08-03 2020-09-15 Kagoshima University Anti-HTLV-1 drug and therapeutic agent for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)

Also Published As

Publication number Publication date
TW202408577A (zh) 2024-03-01
JP2024095754A (ja) 2024-07-10
KR20210034055A (ko) 2021-03-29
CN112566664B (zh) 2023-08-25
CN112566664A (zh) 2021-03-26
CN116942831A (zh) 2023-10-27
PE20211376A1 (es) 2021-07-27
JPWO2020017629A1 (ja) 2021-08-02
ZA202101113B (en) 2022-07-27
CN116850291A (zh) 2023-10-10
JP2022180487A (ja) 2022-12-06
JP2025134820A (ja) 2025-09-17
CA3112511A1 (en) 2020-01-23
EP3824907B1 (en) 2025-09-17
SG11202100561QA (en) 2021-02-25
IL280257A (en) 2021-03-25
WO2020017629A1 (ja) 2020-01-23
EP3824907A1 (en) 2021-05-26
TWI825131B (zh) 2023-12-11
EP3824907A4 (en) 2022-05-04
EP4656657A3 (en) 2026-02-25
JP7475011B2 (ja) 2024-04-26
AU2019306721A1 (en) 2021-03-11
PH12021550134A1 (en) 2021-09-27
EP4656657A2 (en) 2025-12-03
MX2021000732A (es) 2021-04-28
CN116785439A (zh) 2023-09-22
JP7703174B2 (ja) 2025-07-07
BR112021000949A2 (pt) 2021-04-27
AU2019306721B2 (en) 2024-09-05
JP7150286B2 (ja) 2022-10-11
TW202019482A (zh) 2020-06-01
US20210269535A1 (en) 2021-09-02

Similar Documents

Publication Publication Date Title
CL2019001411A1 (es) Métodos para inhibición de la fibrosis en un sujeto en necesidad de ellos. (divisional solicitud 201801817)
MX2020005651A (es) Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
CL2018002991A1 (es) Formulaciones de un inhibidor de lsd1.
MX2022012931A (es) Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
CR20190162A (es) Métodos para usar un anticuerpo biespecífico que reconoce el factor de coagulación ix y/o el factor de coagulación ix activado y el factor de coagulación x y/o el factor de coagulación x activado
EA202191185A1 (ru) Способы ингибирования ангиогенеза у пациента
EA202193019A1 (ru) Лечение наследственного ангионевротического отека
CL2025000404A1 (es) Anticuerpo anti-lilrb1 y usos del mismo
EA201892625A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ С ПРИМЕНЕНИЕМ ИНГИБИТОРА АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ (ACC) ДЛЯ ЛЕЧЕНИЯ НЕАЛКОГОЛЬНОЙ ЖИРОВОЙ БОЛЕЗНИ ПЕЧЕНИ
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
EA201791736A1 (ru) Комбинированная терапия для лечения рака
MX2014006241A (es) Metodos de tratamiento usando un anticuerpo contra interferon gamma.
MX2021000516A (es) Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
MX2019007161A (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2023006511A (es) Un anticuerpo monoclonal inhibidor del factor xiia.
CR20220280A (es) Terapia de combinación que comprende un inhibidor de alk2 y un inhibidor de jak2
EA201990976A1 (ru) Новый способ профилактического лечения непроизвольной потери массы
PE20230255A1 (es) Anticuerpo anti-ox40 y usos del mismo
MX2018000135A (es) Terapia combinada con un conjugado de farmaco y anticuerpo anti receptor 2 de factor de crecimiento epidermico humano (her2) y un inhibidor de linfoma de celulas b2 (bcl-2).
PH12021552967A1 (en) Treatments of angioedema
MX2023014500A (es) Medicamento para el tratamiento y/o prevencion de cancer.
CL2021000585A1 (es) Métodos para tratar la pancreatitis
ECSP11011405A (es) Terapia de combinación que usa un agente o agentes anti-egfr e inhibidores específicos de igf-1r
MX2019014784A (es) Tratamiento para la migra?a.
MX2025005069A (es) Autorregulacion de agentes terapeuticos